A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

• Status: Recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Crinetics Pharmaceuticals Inc.

Criteria

Inclusion Criteria:

1. Male and female subjects ≥18 years of age

2. Confirmed diagnosis of acromegaly and either medically naïve, not currently treated, or willing to washout during the study screening period.

3. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control

4. Willing to provide signed informed consent

Exclusion Criteria:

1. Pituitary radiation therapy within 3 years of Screening

2. Prior treatment with paltusotine

3. History of ineffective or intolerance to octreotide or lanreotide

4. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years

5. Use of any investigational drug within the past 30 days or 5 half-lives, whichever is longer

6. Known history of HIV, hepatitis B, or active hepatitis C

7. History of alcohol or substance abuse in the past 12 months

8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study

9. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities

10. Subjects with symptomatic cholelithiasis

11. Subjects with clinically significant abnormal findings during the Screening Period, or any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study

12. Subjects currently taking lanreotide (within 16 weeks prior to Screening); pasireotide LAR (within 24 weeks prior to Screening); or pegvisomant, dopamine agonists, or combination acromegaly therapy (with 12 weeks prior to Screening)